Is Tharimmune Inc. (THAR) overvalued? · $187.4M cap
Tharimmune Inc. (THAR) is a biotechnology company listed on NASDAQ.
This page asks whether Tharimmune Inc. (THAR) looks expensive on cached numbers — not a short thesis.
No cached income statement for THAR, so there is no earnings base to call rich or cheap.
THAR currently screens at market cap $187.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next THAR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the THAR stock page for the full model, not this heading.
Not investment advice.